1. Hypofractionated radiotherapy to become the new standard of care – 5 year results from the CHHiP trial

The long-awaited CHHiP (Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer) trial results were published last month in Lancet Oncology. The phase 3 non-inferiority trial, led by the ICR’s Prof David Dearnaley and involving 3,163 participants, showed that hypofractionated radiotherapy using 60 Gy in 20 fractions is non-inferior to conventional fractionation using 74 Gy in 37 fractions. The study recommended this as a new standard of care for external-beam radiotherapy of localised prostate cancer (since men can now make 17 fewer hospital trips without compromising on effectiveness) and we are working with Prof Dearnaley’s team to ensure widespread roll-out.

Read about the trial results in more detail on our website here.

2. mpMRI scans will help men avoid unnecessary prostate biopsy – results from PROMIS

An ASCO 2016 highlight was the much anticipated PROMIS (PROstate MRI Imaging Study) results, led by Prof Mark Emberton and Dr Hashim Ahmed from UCL. The results from 576 men showed the mpMRI sensitivity was 93% [95%CI 88-96], specificity was 41% [36-46], PPV was 51% [45-56] and NPV was 89% [83-94]. This means that using mpMRI as a triage test would, at a minimum, avoid a primary biopsy in 158 (27%) men with 14 (2%) fewer cases of clinically significant cancer detected. Second, if biopsy targeted to mpMRI findings achieves the sensitivity of TPM-biopsy, triage with mpMRI would again avoid primary biopsy in 158 (27%) but detect 17 (3%) more cases of clinically significant cancer than the standard TRUS-biopsy. Read about the trial results in more detail on our website here.

The results still need to be confirmed in a peer-reviewed publication but here’s how we’ve already been working to turn the results into reality for men.

 

3. Evidence base linking weight to aggressive prostate cancer continues to grow – results from EPIC

EPIC (European Prospective Investigation into Cancer and Nutrition) released new data at the European Obesity Summit (abstract PO1.857) last month which supports previously published research by the WCRF. After 14 years of follow-up with 142,239 men, EPIC has shown a 10% increased risk of getting aggressive (high-grade) prostate cancer per 5kg/m2 (BMI) and a 13% increased risk per 10cm of waist circumference. The latest results also show a 14% increased risk of dying from aggressive prostate cancer per 5kg/m2 and 18% increased risk per 10cm of waist circumference.

These findings may give health professionals another warning sign to look out for. Importantly, unlike the other known risk factors, being overweight is a risk factor that men can proactively do something to change.

Health professional news archive
comments powered by Disqus